DE69739344D1 - T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten - Google Patents

T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten

Info

Publication number
DE69739344D1
DE69739344D1 DE69739344T DE69739344T DE69739344D1 DE 69739344 D1 DE69739344 D1 DE 69739344D1 DE 69739344 T DE69739344 T DE 69739344T DE 69739344 T DE69739344 T DE 69739344T DE 69739344 D1 DE69739344 D1 DE 69739344D1
Authority
DE
Germany
Prior art keywords
cells
spongiform encephalopathy
products
cell
transmissible spongiform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69739344T
Other languages
English (en)
Inventor
Adriano Aguzzi
Michael A Klein
Alex Raeber
Charles Weissmann
Rolf Zinkernagel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Zuerich
Original Assignee
Universitaet Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet Zuerich filed Critical Universitaet Zuerich
Application granted granted Critical
Publication of DE69739344D1 publication Critical patent/DE69739344D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
DE69739344T 1997-12-16 1997-12-16 T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten Expired - Fee Related DE69739344D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01127424A EP1214943B1 (de) 1997-12-16 1997-12-16 T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten
EP97122186A EP0931551B1 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte

Publications (1)

Publication Number Publication Date
DE69739344D1 true DE69739344D1 (de) 2009-05-14

Family

ID=8227810

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69739344T Expired - Fee Related DE69739344D1 (de) 1997-12-16 1997-12-16 T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten
DE69739210T Expired - Fee Related DE69739210D1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme Enzephalopathie
DE69737557T Expired - Fee Related DE69737557T2 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69739210T Expired - Fee Related DE69739210D1 (de) 1997-12-16 1997-12-16 Diagnostik für übertragbare spongiforme Enzephalopathie
DE69737557T Expired - Fee Related DE69737557T2 (de) 1997-12-16 1997-12-16 Verfahren zur Herstellung von Mittel zur Therapie der übertragbaren Spongiformen Enzephalopathie und nicht-infektiösen Blut- und Gewebeprodukten sowie die hergestellten Produkte

Country Status (9)

Country Link
US (1) US20080063600A1 (de)
EP (4) EP1214943B1 (de)
JP (1) JP2002508335A (de)
AT (3) ATE427120T1 (de)
AU (1) AU2613199A (de)
CA (1) CA2348660A1 (de)
DE (3) DE69739344D1 (de)
ES (3) ES2285720T3 (de)
WO (1) WO1999030738A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7917598A (en) * 1997-05-30 1998-12-30 Stefan Weiss Pharmaceutical compositions comprising a soluble laminin receptor precursor or a compound which blocks the interactionof the laminin receptor precursor and prpsc or PrPc
EP1637160A3 (de) 1999-05-07 2006-05-03 Genentech, Inc. Behandlung von Autoimmunkrankheiten mit Antagonisten die Oberflächenmarker von B Zellen binden
GB0110172D0 (en) * 2001-04-25 2001-06-20 Pa Consulting Services Improved analytical test approach for blood
EP1921451A3 (de) 2001-05-22 2008-05-28 Cygene, Inc. Komplement-vermittelte Assays für In-vivo- und In-vitro-Verfahren
KR20090008176A (ko) * 2005-12-08 2009-01-21 사우스다코타주립대학 감염성 프리온의 시험관 내 증식 및 검출 방법
US7601506B2 (en) * 2006-07-28 2009-10-13 Idexx Laboratories, Inc. Identification of leucocytes bearing diagnostic markers for transmissible spongiform encephalopathies
CA2689408A1 (en) * 2007-06-22 2008-12-31 Bayer Schering Pharma Aktiengesellschaft Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease
US9677042B2 (en) 2010-10-08 2017-06-13 Terumo Bct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
US9617506B2 (en) 2013-11-16 2017-04-11 Terumo Bct, Inc. Expanding cells in a bioreactor
EP3613841B1 (de) 2014-03-25 2022-04-20 Terumo BCT, Inc. Passives ersetzen von medien
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US11965175B2 (en) 2016-05-25 2024-04-23 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
EP3656842A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
JP6748221B2 (ja) 2017-04-01 2020-08-26 エーブイエム・バイオテクノロジー・エルエルシー 細胞免疫療法前の細胞毒性プレコンディショニングの代替

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273882A (en) 1985-06-13 1993-12-28 Amgen Method and kit for performing nucleic acid hybridization assays
US5055290A (en) 1985-12-18 1991-10-08 Boehringer Mannehim Gmbh Ciamexone as a selective immunosuppressant
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
US5369119A (en) 1988-07-28 1994-11-29 Boehringer Mannheim Gmbh Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon
WO1997010505A1 (en) * 1995-09-14 1997-03-20 The Regents Of The University Of California ANTIBODIES SPECIFIC FOR NATIVE PrP?Sc¿
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies

Also Published As

Publication number Publication date
EP1215497A1 (de) 2002-06-19
CA2348660A1 (en) 1999-06-24
EP1215497B1 (de) 2009-01-07
EP1214943B1 (de) 2009-04-01
EP0931551B1 (de) 2007-04-04
WO1999030738A3 (en) 1999-10-21
EP0931551A1 (de) 1999-07-28
ES2320314T3 (es) 2009-05-21
AU2613199A (en) 1999-07-05
ATE420355T1 (de) 2009-01-15
EP1214943A1 (de) 2002-06-19
ES2324334T3 (es) 2009-08-05
DE69737557T2 (de) 2007-12-20
WO1999030738A2 (en) 1999-06-24
JP2002508335A (ja) 2002-03-19
DE69737557D1 (de) 2007-05-16
ES2285720T3 (es) 2007-11-16
ATE358497T1 (de) 2007-04-15
US20080063600A1 (en) 2008-03-13
DE69739210D1 (de) 2009-02-26
ATE427120T1 (de) 2009-04-15
EP1044020A2 (de) 2000-10-18

Similar Documents

Publication Publication Date Title
DE69739344D1 (de) T-Zellen Therapeutika für übertragbare Spongiforme Encephalopathie und Methode zur Herstellung von nicht infektiösen Blut-Produkten und von Geweben abgeleiteten Produkten
IL186495A (en) Use of disaccharide-based compounds for the manufacture of medicaments without an exogenous antigen for prophylactic and therapeutic treatment of infectious and other diseases
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
ATE418562T1 (de) Ctl epitope des epstein-barr virus
ATE364406T1 (de) Methode zur virusinaktivierung
DE69106586D1 (de) Verwendung von Baclofen zur Herstellung von Arzneimitteln zur Behandlung von Angina pectoris.
EP0841392A3 (de) Attenuierter lebender Neospora Impfstoff
ATE132757T1 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
ES495939A0 (es) Un procedimiento de preparacion de una vacuna de virus vivosde la peritonitis infecciosa de los felinos
NO920331L (no) Biologisk preparat samt bruk derav
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
Bach et al. Acute toxoplasmic encephalitis in a normal adult
DK0516725T3 (da) Ny anvendelse af Linomide
ATA77095A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen, enthaltend eine aktive gerinnungsfördernde stubstanz
FR2712493B1 (fr) Utilisation de photosensibilisateurs dérivés du noyau phorbine pour la décontamination du sang infecté par des parasites et/ou des virus.
ATE80553T1 (de) Behandlung von viraler infektion.
ATE71299T1 (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen.
DE60229624D1 (de) Peroxiredoxin-arzneistoffe zur behandlung einer hiv-1-infektion
ES2137544T3 (es) Procedimiento para la preparacion de un preparado biologico terapeutico sin riesgo de infeccion por virus.
Priya et al. Novel Approach to the Clinical Management of Completely Edentulous Hepatitis B Carrier Patient
Kingdon Agents causing non-A non-B hepatitis: Could one be a prion?
EA199700353A1 (ru) Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции
FR2829503B1 (fr) Nouvelee methode d'analyse des caracteristiques phenotypiques des virus de l'immunodeficience humaine(vih)
DE3883754D1 (de) Mittel zur prophylaxe und behandlung von viralen infektionskrankheiten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee